Related Experiment Video
Updated: Sep 8, 2025
07:50
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
4.7K
Reperfusion injury in STEMI: a double-edged sword
Krupa Sara Thomas1, Divina Mariya Puthooran2, Sudeep Edpuganti2
1Department of Medicine, Faculty of Medicine, Tbilisi State Medical University, Tbilisi, Georgia. krupasara22@gmail.com.
Summary
Reperfusion injury after ST-elevation myocardial infarction (STEMI) worsens heart damage despite rapid treatment. New therapies targeting molecular pathways and AI are needed to improve patient outcomes and cardiac healing.
Area of Science:
- Cardiology
- Molecular Medicine
- Biomedical Engineering
Background:
- ST-elevation myocardial infarction (STEMI) necessitates prompt reperfusion, yet this process can paradoxically cause reperfusion injury, exacerbating cardiac damage.
- Mechanisms of reperfusion injury include oxidative stress, calcium overload, mitochondrial dysfunction, and programmed cell death, leading to impaired myocardial healing and prognosis.
Purpose of the Study:
- To conduct a comprehensive narrative review of reperfusion injury in STEMI, focusing on its pathophysiology, clinical impact, and emerging therapeutic strategies.
- To highlight recent advancements in biomarkers, imaging, artificial intelligence, and treatment modalities for mitigating reperfusion injury.
Main Methods:
- A narrative review of peer-reviewed literature from 2015-2025, sourced from ScienceDirect, PubMed, and Google Scholar.
- Emphasis on molecular mechanisms, clinical manifestations (myocardial stunning, no-reflow), diagnostic tools (cardiac MRI, biomarkers), and therapeutic interventions (conditioning, pharmacological agents).
Main Results:
- Reperfusion injury involves complex molecular pathways including reactive oxygen species, calcium dysregulation, and mitochondrial pore opening, contributing to adverse outcomes like heart failure.
- Current diagnostic tools like cardiac MRI and biomarkers (NT-proBNP, sST2) aid risk stratification, but many promising therapies have shown inconsistent efficacy in clinical trials.
- Mechanical conditioning techniques and pharmacological approaches are being investigated, alongside AI for risk assessment and early diagnosis.
Conclusions:
- Reperfusion injury remains a significant barrier to optimal recovery post-STEMI, underscoring the need for adjuvant therapies beyond standard revascularization.
- Future directions include molecular-targeted therapies, AI-driven precision medicine, and addressing sex-specific risk factors to reduce cardiac damage and improve long-term outcomes.
